Investors & Media
Adam M. Koppel M.D., PH.D.
Adam M. Koppel, M.D., Ph.D., managing director of the Bain Capital Life Sciences Fund, has been a member of the Dicerna board of directors since April 2017. He first joined Bain Capital Public Equity in 2003 and was a leader within the firm’s healthcare sector until mid-2014; Dr. Koppel rejoined Bain Capital in 2016.
From mid-2014 to mid-2016, Dr. Koppel was executive vice president of corporate development and chief strategy officer at Biogen. Prior to initially joining Bain Capital, Dr. Koppel was an associate principal at McKinsey & Co. in New Jersey, where he served a variety of healthcare companies. In addition to Dicerna, he serves on the boards of directors of Solid Biosciences, PTC Therapeutics and Trevena.
Dr. Koppel received an M.D. and a Ph.D. in neuroscience from the University of Pennsylvania School of Medicine. He also received an M.B.A. from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an A.B. and A.M. in history and science.